Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5919_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •Contributors
- •1. Introduction
- •2. The Initial Phase of Drug Delivery Systems
- •3. Recent Drug Delivery Systems
- •4. Drug Delivery via Carriers
- •5.4 Polymer-Lipid Hybrid Nanoparticles Drug Delivery System
- •5.5 Self-Micro Emulsifying Drug Delivery System
- •5.6 In Situ Gel Drug Delivery System
- •5.8 Targeted Drug Delivery
- •6. Ceramic-Based Drug Delivery System
- •7. Polysaccharide-Based Drug Delivery System
- •8. Closed Loop Insulin Delivery System
- •9. Liposome-Mediated Drug Delivery
- •5. Recent Drug Delivery Systems
- •5.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •10. Dendrimers
- •11. PEGylated Drug Delivery System
- •12. Antibody-Drug Conjugate System
- •13. Mesoporous Silica-Based Drug Delivery
- •14. Transdermal Drug Delivery System
- •15. Hydrogel-Mediated Ocular Drug Delivery
- •16. Challenges with Current Drug Delivery Systems
- •17. Future Direction and Conclusion
- •References
- •1. Introduction
- •2. Pharmacokinetic Principles
- •2.1 Application of the Pharmacokinetic Principle in the Biomedical Fields
- •3. Cell Membrane/Biological Membrane
- •3.1 Passage of Drugs Across Biological Membranes
- •3.1.1 Simple Transport
- •3.1.2 Specialized Transport
- •4. Routes of Drug Administration
- •4.1 Oral (Enteral) Versus Parenteral Administration
- •4.2 Various Routes of Drug Administration
- •5. Absorption
- •5.1 Factors Affecting Absorption of Drugs
- •5.1.1 Physio-chemical Characteristics
- •5.1.2 Dosage Form
- •5.1.3 Concentration and Volume
- •5.1.4 Blood Flow
- •5.1.5 Surface Area
- •5.1.6 Administration Route
- •5.1.7 Disease States
- •5.2 Gastrointestinal Tract
- •5.3 Parenteral Sites
- •5.4 Pulmonary Sites (Alveoli)
- •5.5 Topical Sites
- •6. Distribution
- •6.1 Factors Affecting Distribution of Drugs
- •6.1.1 Physicochemical Properties of the Drug
- •6.1.2 Binding to Plasma and Tissue Proteins
- •6.1.3 Blood Flow and Organ Size
- •6.1.4 Specialized Compartments and Barriers
- •6.1.5 Specialized Transport Systems
- •6.1.6 Disease States
- •6.1.7 Physiological Factors
- •7. Metabolism/Biotransformation
- •7.1 Functions of Metabolism
- •7.2 Sites of Metabolism
- •7.3.1 Microsomal Enzymes
- •7.3.2 Non-microsomal Enzymes
- •7.4 Pathways of Biotransformation
- •8. Excretion
- •8.1 Routes of Excretion
- •8.1.1 Renal Excretion of Drugs
- •8.1.2 Extra-Renal Excretion of Drugs
- •9.1 Minimum Effective Concentration (MEC)
- •9.2 Maximum Safe Concentration (MSC) or Minimum Toxic Concentration (MTC)
- •9.4 Area Under the Curve (AUC)
- •9.5 Peak Effect
- •9.7 Onset of Action
- •9.8 Onset Time
- •9.9 Duration of Action
- •10. Order of Pharmacokinetic Processes
- •10.1 Zero-Order Kinetics
- •10.2 First-Order Kinetics
- •10.3 Mixed-Order Kinetics
- •11. Pharmacokinetic Models
- •11.1 Compartmental Models
- •11.3 Physiological Models
- •12. Determinants of Pharmacokinetics
- •12.1 Absorption
- •12.1.1 Bioavailability
- •12.1.2 Bioequivalence
- •12.1.3 Area Under Curve (AUC)
- •12.2 Distribution
- •12.2.1 Volume of Distribution
- •12.3 Elimination
- •12.3.2 Clearance (Cl) or Body Clearance
- •13. Conclusion
- •References
- •1. Introduction
- •2. Principles of Targeted Drug Delivery
- •3.1 Changes in pH and Salt Development
- •3.7 Dendrimers
- •4.1 Small-Sized Molecule-Based Targeting Strategies
- •4.2 Nucleic Acid Fragment-Based Targeting Strategies
- •4.3 Peptide- and Antibody-Based Targeting Strategies
- •4.4 Cell-Based Targeting Strategies
- •5. Conclusion
- •References
- •3.4 Liposomes
- •3.5 Solid Lipid Nanoparticles
- •3.6 Co-crystal Preparation
- •1. Introduction
- •2. History
- •3.1 Organic Nanoparticles
- •3.2 Inorganic Nanoparticles
- •4. Nanotechnology-Based Drug Delivery Systems
- •4.1 Smart Drug Delivery Systems
- •4.3 Multifunctional Drug Carriers
- •4.4 Organic/Inorganic Composites
- •5. Nanoparticulate Drug Delivery Systems
- •5.1 Liposomes
- •5.2 Microemulsions
- •5.3 Nanoparticles
- •6. Applications
- •6.1 Enhanced Drug Delivery
- •6.2 Overcoming Biological Barriers
- •6.3 Controlled Drug Release
- •6.4 Combination Therapy
- •6.5 Personalized Medicine
- •7. Limitations
- •7.1 Complexity and Cost
- •7.2 Biocompatibility and Toxicity
- •7.3 Stability and Shelf Life
- •7.4 Drug Loading and Release
- •7.5 Biological Barriers and Clearance
- •8. Conclusions
- •References
- •1. Introduction
- •2. Guidelines for Design of Lipid-Based Formulations
- •3. Formulation Strategies
- •3.1 Lipid Nanoparticles
- •3.1.1 Solid Lipid Nanoparticles (SLNs)
- •3.1.2 Nanostructured Lipid Carriers (NLCs)
- •3.2 Liposomes
- •3.2.1 Conventional Liposomes
- •3.2.2 PEGylated Liposomes
- •3.2.3 Multifunctional Liposomes
- •3.3 Microemulsions and Self-micro Emulsifying Drug Delivery Systems (SMEDDS)
- •3.4 Hybrid Systems
- •3.4.1 Lipid-Polymer Hybrid Nanoparticles
- •3.4.2 Lipid-Protein Hybrid Systems
- •4. Advanced Characterization Methods
- •4.1 In Vitro and In Vivo Assessment
- •4.1.1 Dissolution Studies
- •4.1.2 Permeability Studies
- •4.2 Imaging Techniques
- •4.2.1 Electron Microscopy
- •4.2.2 Fluorescence Imaging
- •Fluorescent Probes
- •Confocal Microscopy
- •4.2.3 Magnetic Resonance Imaging (MRI)
- •4.3 Stability Studies
- •4.3.1 Oxidative Stability
- •4.3.2 Thermal Stability
- •5. Applications of Lipid-Based Drug Delivery Systems
- •5.1 Cancer Therapy
- •5.1.1 Targeted Drug Delivery
- •5.1.2 Combination Therapy
- •5.2 Central Nervous System Disorders
- •5.2.2 Neuroprotective Effects
- •5.3 Antiviral and Antimicrobial Applications
- •5.3.1 Lipid Nanoparticles for Antiviral Drugs
- •5.3.2 Antibiotic Delivery Systems
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •3. Design and Characterization of Polymeric Drug Delivery Systems
- •4. Responsive Polymers
- •4.1 Polymeric Hydrogels
- •4.1.1 Characterization of Polymeric Hydrogels
- •Structural Analysis
- •Functional Analysis
- •4.2 Polymeric Micelles
- •4.2.1 Characterization of Polymeric Micelle
- •Critical Micelle Concentration Determination (CMC)
- •Morphological Characterization
- •Physicochemical Characterization
- •4.3 Liposomes
- •4.3.1 Ethosome
- •4.3.2 Transferosome
- •4.3.3 Niosome
- •4.4 Polyplexes or Polymer-Drug Conjugates
- •4.4.1 Dendrimers
- •4.4.2 Polymer-Protein Conjugates
- •4.4.3 Polymeric Nanoparticles
- •5. Conclusion
- •6. Future Prospects
- •References
- •1. Introduction
- •2.1 Types of Stimuli
- •3. Mechanism of Stimuli Responsiveness
- •3.1 pH-Responsive Systems
- •4. Materials
- •4.1 pH-Responsive Materials
- •4.4 Synthetic Thermo-Responsive Materials
- •4.7 Magnetic Responsive Materials
- •4.8.1 Intrinsically Conducting Polymers
- •4.8.2 Hydrogels
- •5. Methods
- •5.1 pH-Responsive Drug Delivery Systems
- •6. Conclusion
- •7. Notes
- •References
- •1. Introduction
- •3. Basic Features Required for the Biomaterial
- •4. Characteristics of Biomaterials
- •6. Biocompatibility as the Crucial Item
- •7. Biomaterials in Drug Delivery
- •8. Controlled Drug Delivery
- •9. Clinical Need for Controlled Drug Delivery
- •10. Biomaterials for Controlled Release of Small Molecules
- •11. Bioresponsive Polymers: From Design to Implementation
- •11.3 Hydrolysis and Enzymatically Responsive Polymers
- •11.7 Swelling and Contracting Polymers
- •12. Transdermal Drug Delivery Systems
- •12.1 Barriers to Transdermal Delivery
- •12.2 Development of Transdermal Drug Delivery Patches
- •12.3 Hydrogels Versus Non-hydrogel Polymeric Patches
- •12.4 Patches Based on Biopolymers
- •12.5 Patches Based on Synthetic Polymers
- •12.6 Drug Particles/Carriers
- •12.7 Commercial Patches
- •13. Smart Biomaterials
- •14. Conclusion and Future Perspective
- •References
- •1. Introduction
- •1.1 Historical Evolution
- •2. Skin Anatomy and Physiology
- •2.1 Cutaneous Layer Organization
- •2.2 Cutaneous Barrier Function
- •3. Mechanisms of Transdermal Drug Delivery
- •4. Formulation Strategies for Transdermal Drug Delivery
- •4.1 Drug Selection Criteria
- •4.2 Vehicle and Excipient Considerations
- •4.3 Permeation Enhancers
- •4.4 Transdermal Drug Delivery Technologies
- •5. Evaluation Methods for Transdermal Drug Delivery Systems
- •6. Applications of Transdermal Drug Delivery
- •6.1 Therapeutic Areas
- •6.2 Case Studies of Successful Transdermal Products
- •7. Regulatory Considerations and Approval Process
- •7.1 FDA Guidelines for Transdermal Drug Delivery Systems
- •7.2 Quality Control and Manufacturing Standards
- •7.3 Clinical Trial Requirements
- •8. Challenges and Future Perspectives
- •8.1 Overcoming Cutaneous Barrier Properties
- •8.2 Expanding the Range of Deliverable Drugs
- •8.3 Intelligent and Responsive Transdermal Systems
- •8.4 Integration with Other Drug Delivery Technologies
- •8.5 Conclusion
- •References
- •1. Background
- •2. Importance of the Tumor Microenvironment (TME) in Cancer Progression and Therapy
- •2.1 Components of the TME
- •2.2 Therapeutic Targeting of the TME
- •2.3 Impact of Standard Therapies on the TME
- •3. Tumor-Homing Peptides
- •3.1 Different Strategies for Targeting Peptides to Tumor Microenvironment
- •3.2 Applications and Development
- •3.3 Examples and Discoveries
- •4. Tumor Microenvironment Responsive Drug Delivery Systems (DDSS)
- •5. Nanoparticle-Based Smart Drug Delivery Systems
- •5.1.1 Endogenous Stimulus-Responsive Drug Delivery Systems (DDSs)
- •5.1.2 Exogenous Stimulus-Responsive DDSs
- •5.2.2 Dynamic Strategies for Tumor Targeting
- •6. Challenges and Opportunities for Targeted Delivery to Cancer Cells
- •7. Future Directions
- •8. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Types of Biosensors
- •2.1.2 Smart Polymers
- •2.1.3 Microfabricated Devices
- •2.2.1 Enzyme-Based Biosensors
- •2.2.2 Antibody-Based Biosensors
- •2.2.3 Aptamer-Based Biosensors
- •2.2.4 Whole-Cell-Based Biosensors
- •3. Methods
- •3.1 Approach Toward Designing Biosensors
- •3.1.1 Selection of the Analyte and Bioreceptors
- •3.1.2 Immobilization of Biosensors
- •3.1.3 Selection of Transducer
- •3.2 Green Biosensors
- •3.3 Challenges in Development of Biosensors-Based Drug Delivery Systems
- •References
- •1. Introduction
- •3. Ocular Barriers Hindering Absorption of Drugs
- •3.1 Precorneal Barriers
- •3.1.1 Tear Film, Tear Turnover, and Nasolacrimal Duct Drainage
- •3.1.3 Conjunctival and Scleral Barriers
- •3.2 Corneal Barrier
- •3.3 Blood-Ocular Barriers
- •4. Various Routes for Ocular Drug Delivery
- •4.1 Topical Administration
- •4.2 Subconjunctival Administration
- •4.3 Transscleral Administration
- •4.4 Intracameral Administration
- •4.5 Intravitreal Injections/Implants (IVIs)
- •4.6 Retrobulbar Administration
- •4.7 Systemic Administration
- •5. Nanotechnology-Based Ocular Drug Delivery Platforms
- •5.1 Nanoparticles (NPs)
- •5.1.1 Polymeric Nanoparticles (PNPs)
- •5.2 Nanomicelles
- •5.3 Nanoemulsions (NEs)
- •5.4 Nanosuspensions
- •5.5 Nanocrystals (NCs)
- •5.6 Liposomes
- •5.7 Microemulsions
- •5.8 Niosomes
- •5.10 Dendrimers
- •5.11 Nanowafers
- •5.12 Cubosomes
- •5.13 Bilosomes
- •5.14 Olaminosomes
- •5.15 Contact Lenses
- •5.16 Hydrogels
- •5.17 Microneedles (MNs)
- •6. Alternative Ocular Drug Delivery Approaches
- •6.1 Gene Therapy
- •6.1.1 Viral Vectors
- •6.1.2 Non-viral Vectors
- •6.1.3 Antisense Oligonucleotides (ASOs), RNAi, CRISPR-Cas9
- •6.2 Exosomes
- •6.3 Self-nano Emulsifying Drug Delivery Structures (SNEDDS)
- •7. Clinical Status of Nanotechnology-Based Ocular Drug Delivery Systems
- •8. Future Outlooks
- •References
- •1. Introduction
- •2. Anatomy and Physiology of GIT
- •2.1 Mouth and Esophagus
- •2.2 Stomach
- •2.3 Small Intestine
- •2.4 Ruminant Digestive System
- •3. Blood Supply
- •4. Nerve Supply
- •5. Challenges in GIT Drug Delivery
- •5.1 Acidic Environment of the Stomach
- •5.2 Alkaline pH of the Intestine
- •5.3 Variable GI Transit Times
- •6. Future Opportunities in GIT Drug Delivery
- •6.1.1 Targeted Delivery Systems
- •6.1.2 Ligand-Conjugated Nanoparticles
- •6.1.3 Liposomes
- •6.1.4 Solid Lipid Nanoparticles
- •6.2 Controlled Release Systems
- •6.2.1 Osmotic Pumps
- •6.2.2 Matrix Systems
- •6.3 Mucoadhesive Systems
- •6.3.1 Mucoadhesive Polymers
- •6.4 Absorption Enhancers
- •6.5 Tight Junction Modulators
- •6.6 Development of Prodrugs
- •7. Conclusion
- •References
- •1. Introduction
- •2. Anatomy and Physiology of the Respiratory System
- •3. Traditional Methods of Respiratory Drug Delivery
- •3.1 Metered-Dose Inhalers (MDIs)
- •3.2 Dry Powder Inhalers (DPIs)
- •3.3 Nebulizers
- •3.5 Improved Patient Compliance Through User-Friendly Devices
- •3.8 Enhanced Absorption by Overcoming Biological Barriers
- •3.9 Macromolecule Delivery Facilitation
- •3.10 Reduced Side Effects Through Improved Targeting
- •3.11 Formulation Challenges Addressed
- •3.12 Smart Technology Integration for Personalized Treatment
- •3.13 Environmental Sustainability Considerations
- •4. Novel Drug Delivery Approaches
- •4.2 Liposomal Formulations
- •5. Advanced Inhalation Devices
- •6. Targeted Drug Delivery Strategies
- •6.2 pH-Responsive Drug Release
- •7. Emerging Therapeutics for Respiratory Diseases
- •8.2 Combination Therapies
- •8.3 Prodrug Approaches
- •9. Personalized Medicine in Respiratory Drug Delivery
- •10. Future Perspectives and Emerging Technologies
- •10.1 3D-Printed Inhalers
- •11. Conclusion
- •References
- •1. Introduction
- •2. Delivery of Small Molecules
- •3. Drawbacks of Conventional Drug Delivery System
- •4. Factors Affecting Cardiovascular Drug Targeting System
- •4.1 Particle Shape
- •4.2 Particle Size
- •4.3 Particle Density
- •4.4 Flow Characteristics
- •5. Various Targeted Drug Delivery Systems
- •5.1 Application of Exosomes and EVs (Extracellular Vesicles)
- •5.4 Nanomedicines in Cardiovascular Therapy
- •5.5 PLGA-Based Nanoparticles
- •5.6 Liposomal Delivery Systems
- •5.7 Delivery of Biologicals
- •5.8 RNA-Based Delivery
- •5.9 Therapeutic Proteins and Peptides
- •6. Future Perspectives and Challenges
- •7. Conclusion
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Drugs
- •3. Methods
- •3.1.1 Extrusion-Based 3D Bioprinting
- •3.1.2 Inkjet 3D Bioprinting
- •3.1.3 Light-Based Bioprinting
- •3.1.4 Laser-Assisted Printing
- •3.2 Multiple Drug Delivery
- •3.2.1 Multilayer Films with Capsule-Integrated Polypeptide/Polyelectrolyte
- •3.2.2 Multilayer Shells Using Polypeptides/Polyelectrolytes (PL or PG) and LbL Assembly
- •3.3.1 Physical Stimulation-Responsive Drug Delivery Systems
- •3.3.4 Light-Responsive Drug Delivery Systems (LRDDS)
- •3.4 Small Molecule Delivery System
- •3.4.1 Intraarticular Delivery System
- •3.5 Gene Delivery System
- •3.6 Stem Cell Technology
- •4. Conclusion
- •References
- •1. Introduction
- •2. Importance of Targeted Drug Delivery to the Reproductive System
- •3. Challenges in Drug Delivery to the Reproductive System
- •4. Advances in Drug Delivery Systems
- •4.2 Liposomes
- •4.3 Hydrogels and Biodegradable Polymers
- •4.4 Injectable and Implantable Devices
- •4.5 Micro- and Nano-Needles
- •4.6 Spermbots
- •5.1 Vaginal and Cervical Delivery
- •5.2 Uterine and Intrauterine Delivery
- •5.3 Penile and Testicular Delivery
- •6. Targeted and Precision Medicine Approaches
- •6.1 Hormone Replacement Therapy (HRT)
- •6.2 Gene Therapy and RNA-Based Approaches
- •6.3 Personalized Medicine in Reproductive Disorders
- •7. Therapeutic Applications and Innovations
- •7.1 Infertility and Assisted Reproductive Technologies (ART)
- •7.2 Treatment of Reproductive Cancers
- •7.4 Contraceptive Technologies
- •8. Safety and Regulatory Considerations
- •9. Future Directions and Emerging Trends
- •References
- •1. Introduction
- •2. Liposomes
- •3. Preparation of Liposomes
- •3.1 Reagents
- •3.2 Hydration and Liposome Extrusion
- •3.4 Conjugation
- •3.8 PEGylation
- •3.8.1 Materials Required
- •3.8.2 Procedure
- •3.9 Liposomal Doxorubicin (LD)
- •3.10 Marqibo (Vincristine Sulfate)
- •3.11 DepoCyt (Cytarabine)
- •4. Poly(Lactic-co-Glycolic Acid, PLGA) Nanoparticles
- •4.2 Methods
- •4.2.1 Reagents
- •4.2.2 Procedure
- •5. Polycaprolactone (PCL)
- •5.2 pH Sensitivity and Stability
- •5.3 Methods
- •5.3.1 Materials
- •5.4 Drug Loading
- •6. Chitosan-Based Systems
- •6.1 Encapsulation of Nucleic Acids and Proteins
- •6.3 pH Sensitivity and Stability of Chitosan Nanoparticles
- •6.4 Methodology
- •6.4.1 Reagents
- •6.4.2 Procedure
- •7. Dendrimers
- •7.1 Antisense Oligonucleotides
- •7.2 Small-Interfering RNA (siRNA)
- •7.4.1 Divergent Method
- •7.4.2 Convergent Method
- •8. Challenges in Developing Orphan Drugs
- •References
- •1. Introduction
- •2. Vaccine Delivery Systems
- •3. Polymers
- •4. Non-biodegradable NPs
- •5. Calcium Phosphate NPs
- •6. Colloidally Stable Nanoparticles
- •7. Proteasomes
- •8. Liposomes
- •9. Virus-like Particles (VLPs) and Virosomes
- •10. Immune-Stimulating Complexes ISCOMs
- •11. Emulsion Delivery Systems
- •12. Exosome-Based Vaccine Delivery System
- •13. Immunotherapy Using Nano- and Microparticles
- •14. Properties and Role of Nanoparticles in Drug Delivery
- •15. Biomimicry
- •16. Micellar Systems
- •17. Hydrogels
- •18. Edible Vaccines
- •19. Plant-Derived Viruses
- •20. Melt-in Mouth Strips
- •21. Transdermal Delivery
- •22. Delivery of Nucleic Acids
- •23. mRNA Delivery
- •24. Delivery of Cytokines
- •25. DC Targeting
- •26. Drug Delivery Targeting T Cells
- •27. Conclusions
- •References
- •1. Introduction
- •2. Materials
- •2.1 Equipment
- •2.2 Reagents and Solutions
- •3. Methods
- •3.1 Adenovirus
- •3.3 Retroviral Vectors (RV)
- •3.4 Lentivirus (LV)
- •4. Conclusion
- •References
- •1. Introduction
- •2. Technologies Utilizing Cells in Treating Diseases
- •2.1 Somatic Cell Technologies
- •2.2 Immortalized Cell Lines
- •2.5 Genome Editing Technologies
- •2.6 Cell Plasticity Technologies
- •3. Different Kinds of Cells Are Utilized in the Process of Cell Treatment
- •4. The Practices of Regenerative Medicine and Cell Therapy
- •4.1 Veterinary Medicine Therapeutic Uses
- •5. Advancements and Challenges in Drug Delivery
- •6. Drug Delivery Systems and Applications
- •6.2 Drug Nanocarriers Based on Hyaluronic Acid
- •6.3 Hexagonal Boron Nitride Nanosheet Drug Delivery System
- •6.4 Polymer-Lipid Hybrid Nanoparticles
- •6.6 In Situ Gel Drug Delivery System

Methods in Pharmacology
and Toxicology
Abhishek Pathak
Satya Pal Singh Editors
Next-Generation
Drug Delivery
Systems

Next-Generation Drug Delivery Systems

M
E T H O D S I N P HARMACOLOGY AND
T
OXICOLOGY
Series Editor
Y. James Kang
Department of Pharmacology and
Toxicology, University of Louisville
Louisville, USA
For further volumes:
http://www.springer.com/series/7653

Methods in Pharmacology and Toxicology publishes cutting-edge techniques, including methods, protocols, and other hands-on guidance and context, in all areas of pharmacological
and toxicological research. Each book in the series offers time-tested laboratory protocols
and expert navigation necessary to aid toxicologists and pharmaceutical scientists in laboratory testing and beyond. With an emphasis on details and practicality, Methods in Pharma-
cology and Toxicology focuses on topics with wide-ranging implications on human health in
order to provide investigators with highly useful compendiums of key strategies and
approaches to successful research in their respective areas of study and practice.

Next-Generation Drug Delivery
Systems
Edited by
Abhishek Pathak
Department of Veterinary Pharmacology and Toxicology, Apollo College of Veterinary Medicine, Jaipur,
Rajasthan, India
Satya Pal Singh
College of Veterinary and Animal Sciences, Govind Ballabh Pant University of Agriculture and Technology,
Pantnagar, Uttarakhand, India

Editors
Abhishek Pathak
Department of Veterinary
Pharmacology and Toxicology
Apollo College of Veterinary Medicine
Jaipur, Rajasthan, India
Satya Pal Singh
College of Veterinary and Animal Sciences
Govind Ballabh Pant University of Agriculture and Technology
Pantnagar, Uttarakhand, India
ISSN 1557-2153 ISSN 1940-6053 (electronic)
ISBN 978-1-0716-4553-6 ISBN 978-1-0716-4554-3 (eBook)
https://doi.org/10.1007/978-1-0716-4554-3
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Business Media, LLC, part
of Springer Nature 2025
This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part
of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation,
broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and
retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter
developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply,
even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations
and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to
be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty,
expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been
made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This Humana imprint is published by the registered company Springer Science+Business Media, LLC, part of Springer
Nature.
The registered company address is: 1 New York Plaza, New York, NY 10004, U.S.A.
If disposing of this product, please recycle the paper.

Preface
The advancement of drug delivery systems has revolutionized modern therapeutics, paving
the way for next-generation solutions that enhance efficacy, safety, and patient compliance.
This book, Next-Generation Drug Delivery Systems, delves into the innovative technologies
and strategies reshaping the pharmaceutical landscape. It serves as a comprehensive resource
for understanding the principles, applications, and challenges of cutting-edge drug delivery
mechanisms.
The primary objective of this book is to provide students, researchers, clinicians, and
industry professionals with a detailed yet accessible guide to emerging trends in drug
delivery systems. Topics encompass a wide range of delivery mechanisms, including
nanotechnology-based carriers, controlled-release formulations, targeted delivery systems,
and biologics, with a focus on their role in improving therapeutic outcomes. Emphasis has
also been placed on regulatory challenges, translational research, and the integration of
artificial intelligence in designing advanced drug delivery systems.
This edition aims to bridge the gap between theoretical concepts and practical applications. It is meticulously structured to include fundamental principles, design strategies, and
real-world applications. Each chapter highlights the latest advancements, backed by scientific evidence and clinical relevance, making the content both contemporary and impactful.
The inclusion of high-quality illustrations and tables further enhances the reader’s understanding and engagement.
The book is designed to cater to a diverse audience, including academicians, pharmaceutical scientists, healthcare professionals, and students, while also providing valuable
insights for industry leaders involved in drug development and formulation. It fosters a
deeper understanding of how innovative drug delivery approaches can address critical
challenges, such as enhancing bioavailability, reducing side effects, and achieving precise
drug targeting.
Authored by a team
chapter is curated to ensure consistency, logical flow, and practical utility. We are confident
that this book will serve as an essential reference, offering profound knowledge and fostering
innovation in drug delivery systems.
We express our gratitude to the contributors and reviewers who have enriched this book
with their expertise. We also extend our appreciation to the readers who will carry forward
the knowledge to advance the field of pharmaceutical sciences.
It is our hope that this book not only enriches the reader’s understanding but also
inspires new ideas and advancements in the ever-evolving domain of drug delivery systems.
of exper
ts with vast academic and industrial experience, each
Jaipur, Rajasthan, India Abhishek Pathak
Pantnagar, Uttarakhand, India Satya Pal Singh
v

Contents
Preface . . . . . . . . . . . . . . . . . ................................................... v
Contributors. . . . . . . . . . . . . ................................................... ix
1 Introduction to Drug Delivery System: Past, Present,
and Future Perspectives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Santanu Pal, Dumala Naveen, Tejpal, and Swarup Debroy
2 Fundamentals of Pharmacokinetics and Drug Delivery . . . . . . . . . . . . . . . . . . . . . 29
Asha, Puneet Goyal, Pooja, and Ravi Dabas
3 Targeted Drug Delivery: Principles and Strategies. . . . . . . . . . . . . . . . . . . . . . . . . . 53
Meemansha Sharma, Mamta Meena, Ayushi Vaidhya,
and Thakur Uttam Singh
4 Nanotechnology in Drug Delivery: From Bench to Bedside . . . . . . . . . . . . . . . . . 71
Mounil Mankad, Pranav Anjaria, Sanjay Vaghela,
and Varun Asediya
5 Lipid-Based Drug Delivery Systems: Formulation and Applications . . . . . . . . . . 89
Pratibha Yadav
6 Polymer-Based Drug Delivery Systems: Design and Characterization. . . . . . . . . 111
Afroz Jahan, Milindmitra K. Lonare, Sanweer Khatoon,
and K. Kasturi Devi
7 Stimuli-Responsive Drug Delivery Systems: From Concept
to Clinical Translation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
Manisha, Pritam Pal, Pradyut Das,
and Vishwa Ranjan Upadhyay
8 Biomaterials in Drug Delivery: Design and Applications . . . . . . . . . . . . . . . . . . . . 159
Naveen Kumar
9 Transdermal Drug Delivery: Technology and Applications . . . . . . . . . . . . . . . . . . 185
Pabbathi Shivakumar, Ramya Boinepally,
and Matukumalli Usha Rani
10 Drug Deliver
Sonal Saxena, Sameer Shrivastava, Pradeep Kumar,
and Naveen Kumar
11 Biosensor-Based Drug Delivery Systems: Innovations, Applications,
and Future Perspectives. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
Disha Pant, A. H. Ahmad, and Kamal Pant
12 Ocular Drug Delivery: Overcoming Barriers for Effective Treatment . . . . . . . . . 251
Anuradha Nema
13 Drug Delivery to the Gastrointestinal Tract: Challenges
and Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285
Milindmitra K
and Sivaraman Ramanarayanan
y to Cancer: Targeting the Tumor Microenvironment
. L
onare, Afroz Jahan, Manjinder Sharma,
. . . . . . . . . . 211
vii

viii Contents
14 Drug Delivery to the Respiratory System: Novel Approaches
and Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303
Pabbathi Shivakumar, Ramya Boinepally,
and Matukumalli Usha Rani
15 Drug Delivery to the Cardiovascular System: Application
and Future Prospects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
Pankaj Kumar Umar, Jyoti, Asha, and Sachin Kumar Jain
16 Drug Delivery to the Musculoskeletal System: Localized Therapies
and Repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357
Khumtya Debbarma, Dilip K. Deka, Jadav Sarma,
and Arjun Kafle
17 Drug Delivery to the Reproductive System: Innovations
and Therapeutic Advances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375
Dhaval J. Kamothi, Ayushi Vaidhya, Nabaneeta Smaraki,
and Harsh R. Jogi
18 Drug Delivery in Rare Diseases: Orphan Drugs and Therapies . . . . . . . . . . . . . . 407
Anil Kumar, Manjulendra Kumar, and Sudhir Kumar
19 Drug Delivery to the Immune System: Immunotherapies and Vaccines. . . . . . . 437
Santanu Pal, Dumala Naveen, Bavadharani Mani,
and Reddi Lokeswari
20 Unlocking the Potential of Gene Therapy: Principles
and Therapeutic Applications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461
Vijay Kumar
21 Cell-Based Therapies and Drug Delivery: Advancements
and Challenges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473
Pradeep Kumar Ram, Amit Kumar Jha, Kritika Dhial,
and Abhishek Pathak
22 Artificial Intelligence and Machine Learning in Drug Delivery
Optimization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499
Varun Asediya, Pranav Anjaria, Kritika Dhial,
and Abhishek Pathak
23 In Vitro Models for Drug Delivery Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523
S. Simran Kour, Shivali Khandelwal, Roshni, and Vishal Yadav
24 Ethical and Safety Considerations in Drug Delivery Systems . . . . . . . . . . . . . . . . 547
Rajesh Sudhakar Wakchaure, Kritika Dhial, and Abhishek Pathak
25 Challenges and Future Directions for Next-Generation
Drug Delivery Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 571
Lipika S
a, Shveta Singh, Anjali, and Devojyoti Dutta
arm
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597

Contributors
A. H. AHMAD • Department of Veterinary Pharmacology and Toxicology, College of
Veterinary and Animal Sciences, GB Pant University of Agriculture and Technology,
Pantnagar, Uttarakhand, India
A
NJALI
RANAV ANJARIA
P
University, Anand, Gujarat, India
V
ARUN ASEDIYA
SHA
A
University, Jabalpur, MP, India
R
AMYA BOINEPALLY
University, Hyderabad, Telangana, India
R
AVI DABAS
Bareilly, U.P., India
P
RADYUT DAS
Haryana, India
K
HUMTYA DEBBARMA
Veterinary Science, Assam Agricultural University, Khanapara, Guwahati, India
S
WARUP DEBROY
Institute (ICAR-IVRI), Izatnagar, Bareilly, U.P., India
D
ILIP K. DEKA
Veterinary Science, Assam Agricultural University, Khanapara, Guwahati, India
K. K
PVNRTVU, Warangal, Telangana, India
K
RITIKA DHIAL
Medicine, Jaipur, Rajasthan, India
D
EVOJYOTI DUTTA
Assam Agricultural University, Khanapara, Guwahati, Assam, India
P
UNEET GOYAL
University, Jabalpur, M.P., India
A
FROZ JAHAN
Rampura Phul, Punjab, India
S
ACHIN KUMAR JAIN
Veterinary Science University, Jabalpur, MP, India
A
MIT KUMAR JHA
ARSH R. JOGI
H
Institute, Izatnagar, Bareilly, Uttar Pradesh, India
J
YOTI
University, Jabalpur, MP, India
A
RJUN KAFLE
Veterinary Science, Assam Agricultural University, Khanapara, Guwahati, India
D
HAVAL J. KAMOTHI
of Veterinary Medicine, Jaipur, India
ICAR-CIRC, Meerut, India
•
College of Veterinary Science and Animal Husbandry, Kamdhenu
•
M.B. Veterinary College, Dungarpur, Rajasthan, India
•
Department of Pharmacology and Toxicology, Nanaji Deshmukh Veterinary Science
•
Veterinary Pathology, PV Narsimha Rao Telangana Veterinary
•
Division of Medicine, ICAR-Indian Veterinary Research Institute, Izatnagar,
•
Division of Animal Genetics and Breeding, ICAR-NDRI, Karnal,
•
Department of Veterinary Pharmacology and Toxicology, College of
•
Division of Veterinary Anatomy, ICAR-Indian Veterinary Research
•
Department of Veterinary Pharmacology and Toxicology, College of
•
ASTURI DEVI
Department of Pharmacology and Toxicology, Nanaji Deshmukh Veterinary Science
•
Department of Veterinary Pharmacology and Toxicology, CVSc,
•
Department of Veterinary Microbiology, Apollo College of Veterinary
•
Department of Veterinary Physiology, College of Veterinary Science,
•
Department of Veterinary Medicine, Nanaji Deshmukh Veterinary Science
•
Department of Veterinary Pharmacology and Toxicology, COVS, GADVASU,
•
Department of Pharmacology and Toxicology, Nanaji Deshmukh
•
College of Veterinary Science & Animal Husbandry, Rewa, MP, India
•
Division of Biological Products, ICAR-Indian Veterinary Research
•
Department of Veterinary Pharmacology and Toxicology, College of
•
Department of Veterinary Pharmacology & Toxicology, Apollo College
•
ix
Соседние файлы в папке Библиотека им академика М.И. Перельмана
